T2DM
6
Pipeline Programs
3
Companies
5
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
4
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
2100%
+ 3 programs with unclassified modality
On Market (1)
Approved therapies currently available
U
METFORMIN HYDROCHLORIDEApproved
metformin
Unknown Companyoral2018
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Sciwind BiosciencesChina - Hangzhou
2 programs2
EcnoglutidePhase 3Peptide1 trial
Ecnoglutide high dosagePhase 3Peptide1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
CelltrionMetformin
CelltrionCT-L03 Group 1
Sciwind BiosciencesEcnoglutide high dosage
Sciwind BiosciencesEcnoglutide
Chipscreen BiosciencesChiglitazar
Clinical Trials (5)
Total enrollment: 753 patients across 5 trials
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
Start: Jul 2025Est. completion: Apr 2027171 patients
Phase 3Recruiting
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Start: Aug 2024Est. completion: May 2026582 patients
Phase 3Active Not Recruiting
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
Start: Jan 2023Est. completion: Oct 2024
Phase 3Completed
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients
Start: Dec 2022Est. completion: Oct 2024
Phase 3Completed
Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
Start: Feb 2023Est. completion: Mar 2023
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 753 patients
3 companies competing in this space